Int J Pediatr Otorhinolaryngol:季节性过敏性鼻炎中,DNA甲基化模式鉴定

2019-01-08 AlexYang MedSci原创

最近,有研究人员鉴定了季节过敏性鼻炎中,明显的DNA甲基化模式。研究人员从ArrayExpress数据库中获得了E-GEOD-5022的甲基化概况,并根据甲基化数据对差异共甲基化网络(DCN)进行了构建。从DCN中,研究人员鉴定了多重差异化的模式(M-DMs)。研究人员还将明显的模式定位到具体的途径中,从而鉴定富集的途径。最后,研究人员指出,在DCN中,共鉴定了16个种子基因,并利用这16个种子基

最近,有研究人员鉴定了季节过敏性鼻炎中明显的DNA甲基化模式。研究人员从ArrayExpress数据库中获得了E-GEOD-5022的甲基化概况,并根据甲基化数据对差异共甲基化网络(DCN)进行了构建。从DCN中,研究人员鉴定了多重差异化的模式(M-DMs)。研究人员还将明显的模式定位到具体的途径中,从而鉴定富集的途径。

研究发现,在DCN中,共鉴定了16个种子基因,并利用这16个种子基因来构建M-DMs。统计学分析表明,其中1个模式表现出p<0.05显著性。途径富集分析表明,共涉及了17个途径,且p<0.05;并且大多数途径均与DNA复制有关。

最后,研究人员指出,在SAR中他们鉴定了一个多重差异模式,17个途径通过该差异模式获得,并且是SAR中的重要因子。这些结果能够为SAR中DNA甲基化的分子机制提供新的见解。

原始出处:

Gao Z, Huang M, Qu Z et al. Identification of DNA methylation module in seasonal allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047064, encodeId=b159204e064b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Dec 04 18:26:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727834, encodeId=3e411e2783415, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 27 00:26:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638957, encodeId=202b163895e40, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Oct 19 00:26:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468702, encodeId=bbf11468e027e, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Thu Jan 10 12:26:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533414, encodeId=0ed4153341415, content=<a href='/topic/show?id=fe21454096b' target=_blank style='color:#2F92EE;'>#季节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45409, encryptionId=fe21454096b, topicName=季节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4bd12435949, createdName=charleshjw, createdTime=Thu Jan 10 12:26:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357596, encodeId=b72e35e5961b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Jan 08 23:12:36 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047064, encodeId=b159204e064b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Dec 04 18:26:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727834, encodeId=3e411e2783415, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 27 00:26:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638957, encodeId=202b163895e40, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Oct 19 00:26:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468702, encodeId=bbf11468e027e, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Thu Jan 10 12:26:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533414, encodeId=0ed4153341415, content=<a href='/topic/show?id=fe21454096b' target=_blank style='color:#2F92EE;'>#季节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45409, encryptionId=fe21454096b, topicName=季节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4bd12435949, createdName=charleshjw, createdTime=Thu Jan 10 12:26:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357596, encodeId=b72e35e5961b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Jan 08 23:12:36 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
    2019-08-27 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047064, encodeId=b159204e064b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Dec 04 18:26:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727834, encodeId=3e411e2783415, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 27 00:26:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638957, encodeId=202b163895e40, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Oct 19 00:26:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468702, encodeId=bbf11468e027e, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Thu Jan 10 12:26:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533414, encodeId=0ed4153341415, content=<a href='/topic/show?id=fe21454096b' target=_blank style='color:#2F92EE;'>#季节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45409, encryptionId=fe21454096b, topicName=季节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4bd12435949, createdName=charleshjw, createdTime=Thu Jan 10 12:26:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357596, encodeId=b72e35e5961b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Jan 08 23:12:36 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047064, encodeId=b159204e064b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Dec 04 18:26:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727834, encodeId=3e411e2783415, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 27 00:26:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638957, encodeId=202b163895e40, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Oct 19 00:26:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468702, encodeId=bbf11468e027e, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Thu Jan 10 12:26:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533414, encodeId=0ed4153341415, content=<a href='/topic/show?id=fe21454096b' target=_blank style='color:#2F92EE;'>#季节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45409, encryptionId=fe21454096b, topicName=季节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4bd12435949, createdName=charleshjw, createdTime=Thu Jan 10 12:26:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357596, encodeId=b72e35e5961b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Jan 08 23:12:36 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
    2019-01-10 30397606
  5. [GetPortalCommentsPageByObjectIdResponse(id=2047064, encodeId=b159204e064b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Dec 04 18:26:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727834, encodeId=3e411e2783415, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 27 00:26:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638957, encodeId=202b163895e40, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Oct 19 00:26:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468702, encodeId=bbf11468e027e, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Thu Jan 10 12:26:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533414, encodeId=0ed4153341415, content=<a href='/topic/show?id=fe21454096b' target=_blank style='color:#2F92EE;'>#季节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45409, encryptionId=fe21454096b, topicName=季节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4bd12435949, createdName=charleshjw, createdTime=Thu Jan 10 12:26:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357596, encodeId=b72e35e5961b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Jan 08 23:12:36 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2047064, encodeId=b159204e064b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Dec 04 18:26:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727834, encodeId=3e411e2783415, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 27 00:26:00 CST 2019, time=2019-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638957, encodeId=202b163895e40, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Oct 19 00:26:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468702, encodeId=bbf11468e027e, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Thu Jan 10 12:26:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533414, encodeId=0ed4153341415, content=<a href='/topic/show?id=fe21454096b' target=_blank style='color:#2F92EE;'>#季节性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45409, encryptionId=fe21454096b, topicName=季节性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4bd12435949, createdName=charleshjw, createdTime=Thu Jan 10 12:26:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357596, encodeId=b72e35e5961b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Jan 08 23:12:36 CST 2019, time=2019-01-08, status=1, ipAttribution=)]
    2019-01-08 医者仁心5538

    学习了

    0

相关资讯

Medicine (Baltimore):过敏性鼻炎与阻塞性睡眠呼吸暂停相关性元分析

过敏性鼻炎(AR)与阻塞性睡眠呼吸暂停(OSA)共存是临床实践上的一种常见现象。AR长久以来被认为是OSA的一种风险因子。然而,相关关系仍旧不完全清楚。因此,最近,有研究人员进行了元分析来评估睡眠障碍性呼吸(SDB/)OSA中AR的流行度以及它们之间的关系。元分析总共包括了44个已经报道的研究,总共有6086名参与者。对成年人来讲,SDB患者中AR的流行度为22.8%(95% CI, 15.0-3

Int Arch Allergy Immunol:过敏性鼻炎和哮喘的皮下屋尘螨免疫治疗的临床响应与热带无爪螨敏感无关

屋尘螨(DP)和热带无爪螨(BT)是热带气候中最明显的室内尘螨,并能够诱导过敏性疾病。然而,是否DP皮下免疫治疗(SCIT)的效果在对DP敏感或者对DP和BT都敏感的患者中效果相似还是未知。最近,有研究人员对上述问题进行了探究,研究包括了95名(5-17岁)哮喘携带鼻炎的儿童,并且对DP和BT均敏感,且已经接受了3年的DP-SCIT治疗。在DP-SCIT治疗过程中,研究人员评估了临床症状和药物评分

Eur Rev Med Pharmacol Sci:miR-487b能够通过对IL-33/ST2信号途径的抑制减轻过敏性鼻炎

最近,有研究人员调查了miR-487b/IL-33-ST2途径对过敏性鼻炎(AR)病理的潜在影响和相关的机制。研究人员在患有和不患有过敏性鼻炎的患者中检测了IL-33、磺基转移酶同系物(ST2)和miR-487b的表达水平,并利用荧光素酶报告试验评估了miR-487b与IL-33之间的互作。研究人员还利用小鼠模型来探究miR-487b/IL-33-ST2途径对过敏性鼻炎的影响。研究发现,IL-33

Eur Arch Otorhinolaryngol:过敏原阻滞剂机械阻隔凝胶对过敏性鼻炎患者症状和生活质量效果评估

过敏性鼻炎(AR)是一种非常常见的、慢性的和全球健康问题。在过去的20年中,AR治疗的屏障措施效果已有调查。最近,有研究人员评估了过敏原阻滞剂机械阻隔凝胶(MBG)(AlerjiSTOP®)治疗对患有季节性和永久性过敏性鼻炎患者的症状和生活质量评分(QoLS)的影响。研究是一个单中心、回顾性的研究,在2017年1月和2018年5月之间进行,总共包括了83名患有AR的患者。临床和实验调查表明50(6

Int J Pediatr Otorhinolaryngol:早期家庭环境和疾病情况与过敏性鼻炎相关

尽管对过敏性鼻炎(AR)很关注,但是过敏性鼻炎相关的风险因子仍旧不清楚。最近,有研究人员分析了早期生活的家庭环境和疾病与AR之间的相关性。研究是一个案例-对照研究,包括了242名AR患者和258名健康对照。他们完成了调查问卷来调查早期生活的相关疾病情况、家族过敏历史和家庭环境因素。研究人员调查了与AR相关的40个风险因素并进行了卡方检验和逻辑回归分析。研究发现,母亲患的疾病(比如牙周炎,慢性鼻炎,

Clin Exp Allergy:桦树花粉过敏皮下免疫治疗的效果和安全性评价

之前的桦树花粉皮下免疫治疗的临床试验一般进行1-2年的治疗周期,并且地理位置经常是单一的。最近,有研究人员在19个欧洲中心进行了为期3年的研究,他们评估了高剂量低致敏性桦树花粉过敏原皮下免疫治疗对那些确诊患有中度到重度季节过敏性鼻炎/鼻窦炎患者的治疗效果。研究包括了253名桦树花粉过敏患者,并随机分配到季节前安慰剂组(n=129)和积极治疗组(n=124)。研究发现,积极治疗vs安慰剂治疗患者的症